THE esperion story
Singularly Focused on Lipid Management for Everybody
In spite of advances in lipid management, millions of patients still find it difficult to reach their low‑density lipoprotein cholesterol (LDL-C) target.1   

At Esperion, we’re committed to changing that. Read about our mission and our core values.

We have assembled a world-renowned team of lipid specialists who have been at the forefront of innovation in lipid management for decades.

Our goal: to help patients who still need additional lipid lowering despite taking maximally tolerated statin therapy. With this goal in mind, we are driven to provide patients a novel treatment that not only works to lower LDL-C, but also works safely within their bodies.

Every day, we are focused on this lone objective. Because we believe that to change this treatment paradigm, our company would rather be excellent in just this one disease state, than be good in several.

Our approach is unprecedented in modern pharmaceuticals, and we think it is the right one.

 
Robust Industry Expertise in Cholesterol Biology
Esperion‘s founder, Roger Newton, PhD, co-discovered and helped lead the development of the most successful drug to inhibit HMG-CoA reductase, Lipitor® (atorvastatin calcium).   

This experience allowed Esperion to develop new complementary, non-statin, once-daily, oral small molecule inhibitors that target another key enzyme on the cholesterol biosynthesis pathway, ATP citrate lyase (ACL), which is upstream of HMG-CoA reductase.

To help bring these new, exciting products to market, Esperion has assembled an innovative team of lipid management experts who are exclusively committed to leveraging their scientific and clinical excellence and deep understanding of cholesterol biosynthesis.

The Lipid Management Team is focused on developing targeted, oral, non-statin, LDL-C lowering therapies to address patient needs that have the potential to make a substantial impact on lowering LDL-C.

Read our leadership’s bios

 
 
Our Mission: Developing Innovative Lipid-Modifying Therapies
Esperion is passionately committed to developing and commercializing oral, LDL-C lowering therapies for patients with hypercholesterolemia.
 
 
Our Core Values
Collaboration
We promote an inclusive and supportive environment that, regardless of title or rank, fosters open discussion and debate.
Courage
We challenge the status quo with entrepreneurial spirit as we remain steadfastly committed to problem-solving with agility, resilience, and creativity.
People
We value each other, and we invest in building strong relationships and creating opportunities for personal and professional growth.
Passion
We are committed to making a difference for patients living with hypercholesterolemia and will confront every challenge with optimism and resourcefulness.
Accountability
We hold ourselves and each other to the highest level of personal and professional integrity, by owning what we say and delivering on our commitments.
Collaboration
We promote an inclusive and supportive environment that, regardless of title or rank, fosters open discussion and debate.
Passion
We are committed to making a difference for patients living with hypercholesterolemia and will confront every challenge with optimism and resourcefulness.
Courage
We challenge the status quo with entrepreneurial spirit as we remain steadfastly committed to problem-solving with agility, resilience, and creativity.
Accountability
We hold ourselves and each other to the highest level of personal and professional integrity, by owning what we say and delivering on our commitments.
People
We value each other, and we invest in building strong relationships and creating opportunities for personal and professional growth.
Get company news delivered to your inbox
Reference: 1. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10:1109-1118.   

HMG-CoA=hepatic 3-hydroxy-3-methyl-glutaryl-CoA.